Back to Results

The impact of feminizing gender-affirming hormone therapy on biomarkers of coagulation and thrombosis

Primary Objective

The global aim of this pilot study is to determine whether estrogen plus spironolactone increases levels of certain biomarkers of coagulation and thrombosis in trans women or other persons taking estrogen plus spironolactone for feminizing Gender Affirming Hormone Therapy after six months and twelve months.

Study category: Diabetes & Hormone Disorders

Is this Study for You?

Let's Get Started!

Description

We are enrolling transgender women who are starting feminizing Gender Affirming Hormone Therapy (e. g., estrogen plus spironolactone). They are adults who were assigned male at birth but whose gender identity is female.

Main Procedures Involved: Measuring plasma for certain biomarkers of coagulation and thrombosis at baseline and after six months and twelve months of taking estradiol plus spironolactone.

Duration of Participation: 12 months.

Details
Age

Adult

Phase

Pilot - A pilot Study is used to obtain information, and work out the logistics and management, deemed necessary for further Research Studies.

Type of Study

Observational

Scope

Local

Location

University of Colorado Hospital

Principal Investigator
Sean Iwamoto

Sean Iwamoto

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers